To include your compound in the COVID-19 Resource Center, submit it here.
Amgen Inc. (NASDAQ:AMGN) reported 2Q17 earnings that topped estimates, including sales of hypercholesterolemia drug Repatha evolocumab that exceeded expectations.
Repatha's sales rose to $83
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury